Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendations
Jazyk angličtina Země Anglie, Velká Británie Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
36059237
DOI
10.1093/eurjpc/zwac200
PII: 6691825
Knihovny.cz E-zdroje
- Klíčová slova
- Cholesterol, Familial hypercholesterolaemia, LDL cholesterol, Myocardial infarction, Preventive cardiology,
- MeSH
- dítě MeSH
- genetické testování MeSH
- hyperlipoproteinemie typ II * diagnóza epidemiologie genetika MeSH
- LDL-cholesterol MeSH
- lidé MeSH
- nemoci srdce * MeSH
- plošný screening MeSH
- rizikové faktory MeSH
- veřejná politika MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Evropa epidemiologie MeSH
- Názvy látek
- LDL-cholesterol MeSH
Familial hypercholesterolaemia (FH) is under-recognized and under-treated in Europe leading to significantly higher risk for premature heart disease in those affected. As treatment beginning early in life is highly effective in preventing heart disease and cost-effective in these patients, screening for FH is crucial. It has therefore now been recognized by the European Commission Public Health Best Practice Portal as an effective strategy. Model programmes exist in Europe to identify young individuals with FH, which are based on cascade screening of first-degree relatives of affected individuals, universal screening for high cholesterol, opportunistic screening of high-risk individuals, or a combination of the above approaches. Recommendations presented herein to improve identification of FH emphasize that every country should have an FH screening programme. These programmes should be adapted from existing strategies to best fit the individual country's healthcare system, governments should provide financial support for these programmes and related care, and further research to optimize care and implementations should be conducted.
Cardiovascular Department CCUL CAML Lisbon School of Medicine University of Lisbon Portugal
Centre for Cardiovascular Surgery and Transplantation Pekařská 53 656 91 Brno Czech Republic
Department of Cardiology Hacettepe University Ankara Turkey
DZHK partner site Munich Munich Heart Alliance Munich Germany
Heart Institute University of Sao Paulo Medical School Hospital Sao Paulo Brazil
International Atherosclerosis Society Milan Italy
Medical Faculty Masaryk University Kamenice 5 625 00 Brno Czech Republic
The European FH Patient Network Star House Star Hill Rochester Kent ME1 1UX UK
Citace poskytuje Crossref.org
The time is now: Achieving FH paediatric screening across Europe - The Prague Declaration
